Cevolisiran

RNA / oligonucleotide

Also known as ALXN2030

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Antibody-Mediated Rejection
NCT06744647 · Alexion Pharmaceuticals, Inc.
2025-03-07 – 2028-11-07 · Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
What this study did
Phase 1 (1)
Other / comorbidity
NCT05501717 · Alexion Pharmaceuticals, Inc.
2022-08-16 – 2026-10-14 · Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cevolisiran: this drugPhase 2RNA / oligonucleotideComplement C3not yet gradedNo reviewed efficacy summary
Pegcetacoplan (Empaveli)
Approved(overall)
PeptideComplement C3Partial signal
NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666)
Pegcetacoplan Ophthalmic (Syfovre)
Approved(overall)
PeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
ARO-C3
Phase 1/2(overall)
RNA / oligonucleotideComplement C3not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cevolisiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Antibody-Mediated RejectionActive not recruiting
Est. primary completion 2027-10-11 · NCT06744647 · CT.gov ↗
What to watch

See the full readout calendar ↗